Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Prednisolone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 10/20 | 0.98 |
| ▸ | HIF1A | Q16665 | 9/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.98 |
| ▸ | PGR | P06401 | 5/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.98 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.98 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.98 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.98 |
| ▸ | TNF | P01375 | 1/20 | 0.98 |
| ▸ | IL6 | P05231 | 1/20 | 0.98 |
| ▸ | AR | P10275 | 1/20 | 0.98 |
| ▸ | GLUL | P15104 | 1/20 | 0.98 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.98 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.69 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.69 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prednisolone SCHEMBL5073648 | 1.00 | NR3C1 (0.98) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL5073644 | 1.00 | NR3C1 (0.98) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL503431 | 1.00 | NR3C1 (0.98) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL2737385 | 0.99 | NR3C1 (1.00) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL4449434 | 0.99 | NR3C1 (1.00) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL23863778 | 0.99 | NR3C1 (1.00) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL13044469 | 0.99 | NR3C1 (1.00) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL14420691 | 0.99 | NR3C1 (1.00) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL765329 | 0.99 | NR3C1 (1.00) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Prednisolone SCHEMBL11413677 | 0.99 | NR3C1 (1.00) | NR3C1HIF1AHSD17B10PGRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 211 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4361152-A1 | USE OF PYRROLOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATING CHRONIC GRAFT VERSUS HOST DISEASE | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-05-01 | — | — | EP | claimed |
| US-11969432-B2 | Pharmaceutical composition and use thereof | BARNAS, ARIAN JANKUR CAN (AT) | 2024-04-30 | — | — | US | claimed |
| EP-3883577-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | CASE WESTERN RESERVE UNIVERSITY (US) | 2021-09-29 | — | — | EP | claimed |
| US-10966955-B2 | Ocular drug delivery system and uses thereof | CHANG GUNG UNIVERSITY (TW) | 2021-04-06 | — | — | US | claimed |
| US-20210059980-A1 | OCULAR DRUG DELIVERY SYSTEM AND USES THEREOF | CHANG GUNG UNIVERSITY (TW) | 2021-03-04 | — | — | US | claimed |
| CN-111432740-A | Drug delivery system and method | 亚克安娜生命科学有限公司 | 2020-07-17 | — | — | CN | claimed |
| EP-1605863-B1 | SINUS DELIVERY OF SUSTAINED RELEASE THERAPEUTICS | INTERSECT ENT INC (US) | 2016-09-07 | — | — | EP | claimed |
| WO-2005062761-A2 | STABILIZED PREDNISOLONE SODIUM PHOSPHATE SOLUTIONS | PHARMACEUCTICAL ASSOCIATED LLC (US) | 2005-07-14 | — | — | WO | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-5837698-A | DERIVATIVES OF BETA-METHASONE, DEXAMETHASONE, BUDESONIDE AND TRIAMCINOLOLE WITH NITRATE | G. D. SEARLE & CO. (US) | 1998-11-17 | — | — | US | claimed |
| US-5650170-A | Dosage form for delivering drug at a controlled rate to the intestine and to the colon | ALZA CORPORATION (US) | 1997-07-22 | — | — | US | claimed |
| WO-2024123983-A1 | METHODS OF PREDICTING AND TREATING IMMUNOTHERAPY ADVERSE EVENTS BASED ON IMMUNE CELL POPULATIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-06-13 | — | — | WO | disclosed |
| US-20240194304-A1 | Prediction Method, Prediction Device, and Prediction Program for New Indication of Desired Known Drug or Equivalent Material Thereof | KARYDO THERAPEUTIX, INC. (JP) | 2024-06-13 | — | — | US | disclosed |
| CN-115484943-B | Combination of CXCL8 (interleukin-8) activity inhibitor and corticosteroid, pharmaceutical composition and use thereof | 导博药物公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| CN-1158565-A | aqueous foam composition | TILLOTTS PHARMA AG (CH) | 1997-09-03 | — | — | CN | disclosed |
| EP-0766960-A1 | EXTERNAL PREPARATIONS FOR TREATING DERMATOSES | SEKISUI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1997-04-09 | — | — | EP | disclosed |
| US-5100669-A | Controlled release drug delivery | BIOMATERIALS UNIVERSE, INC. (JP) | 1992-03-31 | — | — | US | disclosed |
| EP-0330180-A1 | Polylactic acid type microspheres containing physiologically active substance and process for preparing the same | Biomaterials Universe, Inc. (JP) | 1989-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | NR3C1 711/4885HIF1A 2098/4885HSD17B10 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.